Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Clinical Rheumatology|July 1, 2005
Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literatureWilke Beuthien, Hans-Ullrich Mellinghoff, Johannes von KempisRheumatology International|March 17, 2005
Soluble CD21 in sera and synovial fluid of arthritic patientsThomas Grottenthaler, Johannes von Kempis, Sigune Goldacker, et al.Health Economics Review|October 2, 2012
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspectiveJan Zeidler, Thomas Mittendorf, Rüdiger Müller, et al.Deutsche Medizinische Wochenschrift (1946)|November 18, 2017
[A Rare Differential Diagnosis of Chronic Cough]Michael Dicker, Tino Schneider, Johannes von Kempis, et al.Immunobiology|March 18, 2003
The combination of different antiphospholipid antibody subgroups in the sera of patients with autoimmune diseases is a strong predictor for thrombosis. A retrospective study from a single centerPhilipp von Landenberg, Jürgen Schölmerich, Johannes von Kempis, et al.Praxis|April 30, 2020
[Gout and Its Management in Clinical Practice]Thomas Langenegger, Andreas Krebs, Thomas Rosemann, et al.Clinical Rheumatology|August 5, 2017
Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE studyRuediger B Mueller, Winfried Graninger, Páris Sidiropoulos, et al.Seminars in Arthritis and Rheumatism|April 22, 2015
Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohortRüdiger B Müller, Johannes von Kempis, Sarah R Haile, et al.Annals of the Rheumatic Diseases|June 29, 2014
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phaseMichael H Schiff, Johannes von Kempis, Ronald Goldblum, et al.Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|July 11, 2009
Abdominal pain in a patient with ankylosing spondylitis under treatment with infliximabJulian Cooper, Beat Flückiger, Birgit Traichl, et al.Pageof 4